Vivos Therapeutics Inc (VVOS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VVOS SEC filings page.
Vivos Therapeutics Inc (VVOS) reported $20.9M in revenue over the twelve months to Jun 30, 2026, up 45.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue recovery remains secondary to a financing-dependent model: costs widened faster than sales, while liquidity tightened into FY2025.
The operating-margin improvement to-74.3% from-125.3% proved fragile as the following year's cost structure reversed it. In FY2025, revenue rose16.0% while SG&A rose55.1% , indicating that operating costs—not gross economics—dominate the loss profile.
Operating cash flow was
The current ratio fell from 1.5x to 0.2x, while current liabilities reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Vivos Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Vivos Therapeutics Inc held $2.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $15.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Vivos Therapeutics Inc scores 7/100 among other emerging companies.
Vivos Therapeutics Inc had 13M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Vivos Therapeutics Inc scores 9/100 among other emerging companies.
Vivos Therapeutics Inc spent $100K on research and development in fiscal year 2025, which was 0.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Vivos Therapeutics Inc scores 5/100 among other emerging companies.
Vivos Therapeutics Inc reported revenue of $17.4M in fiscal year 2025, against $15.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Vivos Therapeutics Inc scores 59/100 among other emerging companies.
Vivos Therapeutics Inc's operations used $15.3M of cash in fiscal year 2025, against $12.7M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Vivos Therapeutics Inc scores 33/100 among other emerging companies.
Vivos Therapeutics Inc's cash, cash equivalents and investments came to $2.0M at the end of fiscal year 2025, against $26.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Vivos Therapeutics Inc scores 13/100 among other emerging companies.
Vivos Therapeutics Inc scores -9.46, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.7M) relative to total liabilities ($26.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Vivos Therapeutics Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Vivos Therapeutics Inc reported a net loss of $21.2M while operations used $15.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Vivos Therapeutics Inc reported an operating loss of $19.9M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Vivos Therapeutics Inc generated $5.2M in revenue in Q2 2026. This represents an increase of 34.9% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.
Vivos Therapeutics Inc's EBITDA was -$4.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.4% from the same quarter a year earlier. Against the prior quarter it is up 30.0%.
Vivos Therapeutics Inc reported -$5.5M in net income in Q2 2026. This represents a decrease of 9.3% from the same quarter a year earlier. Against the prior quarter it is up 28.7%.
Vivos Therapeutics Inc earned -$0.31 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 40.4%.
Cash & Balance Sheet
Vivos Therapeutics Inc recorded an outflow of $3.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 16.4% from the same quarter a year earlier. Against the prior quarter it is up 40.9%.
Vivos Therapeutics Inc held $1.8M in cash against $366K in long-term debt as of Q2 2026, with $20.4M of liabilities due within a year.
Not reported for Q2 2026.
Margins & Returns
Vivos Therapeutics Inc's gross margin was 57.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.2 percentage points.
Vivos Therapeutics Inc's operating margin was -93.6% in Q2 2026, reflecting core business profitability. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
Vivos Therapeutics Inc invested $416K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 46.0% from the same quarter a year earlier. Against the prior quarter it is up 2211.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
VVOS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M+34.9% | $5.1M+70.5% | $3.8M+3.4% | $6.8M+75.7% | $3.8M-5.8% | $3.0M-11.8% | $3.7M+13.9% | $3.9M+16.9% |
| Cost of Revenue | $2.2M+28.7% | $2.1M+38.2% | $838K-71.9% | $2.8M+86.5% | $1.7M+21.9% | $1.5M+1407.0% | $3.0M+3083.0% | $1.5M+1426.0% |
| Gross Profit | $3.0M+40.0% | $3.1M+102.7% | $3.0M+42.4% | $3.9M+68.7% | $2.1M-20.4% | $1.5M-22.1% | $2.1M+0.4% | $2.3M+33.6% |
| SG&A Expenses | $7.1M+11.0% | $9.0M+83.4% | $8.5M+96.5% | $7.9M+75.7% | $6.4M+55.5% | $4.9M-0.6% | $4.3M-20.5% | $4.5M-2.4% |
| Operating Income | -$4.8M+0.8% | -$6.6M-68.8% | -$6.4M-127.3% | -$4.7M-79.0% | -$4.9M-151.3% | -$3.9M-3.5% | -$2.8M+32.1% | -$2.6M+27.3% |
| EBITDA | -$4.3M+5.4% | -$6.2M-64.7% | -$5.9M-123.0% | -$4.3M-74.1% | -$4.6M-154.6% | -$3.7M-2.8% | -$2.7M+33.2% | -$2.5M+28.4% |
| Interest Expense | $1.1M | $1.1M | N/A | $500K | N/A | N/A | N/A | N/A |
| Net Income | -$5.5M-9.3% | -$7.7M-98.8% | -$6.9M-143.8% | -$5.4M-106.4% | -$5.0M-159.7% | -$3.9M-2.7% | -$2.8M+33.6% | -$2.6M-25.0% |
| EPS (Basic) | -$0.31+43.6% | -$0.52-15.6% | -$0.58-107.1% | -$0.49-22.5% | -$0.55+8.3% | -$0.45+72.4% | -$0.28+90.8% | -$0.40+77.1% |
| EPS (Diluted) | -$0.31 | -$0.52 | -$0.58 | -$0.49 | -$0.55 | -$0.45 | -$0.28 | -$0.40 |
| Diluted Shares (Avg) | 18M | 15M | N/A | 11M | 9M | 9M | N/A | 7M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
VVOS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $24.1M-7.3% | $25.0M+122.0% | $25.2M+64.6% | $25.6M+67.1% | $26.0M+64.3% | $11.3M-4.4% | $15.3M+42.4% | $15.3M+48.8% |
| Current Assets | $4.2M-37.4% | $4.8M+33.6% | $4.4M-41.3% | $5.8M-21.8% | $6.7M-14.3% | $3.6M-0.1% | $7.5M+203.7% | $7.4M+272.7% |
| Cash & Equivalents | $1.8M-59.7% | $2.1M-9.9% | $2.0M-67.6% | $3.1M-51.1% | $4.4M-36.2% | $2.3M-10.3% | $6.3M+281.0% | $6.3M+538.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $1.4M-11.9% | $1.8M+146.4% | $1.6M+267.7% | $2.1M+370.0% | $1.6M+313.4% | $718K+36.8% | $430K+112.9% | $454K+99.1% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $8.6M+1.4% | $8.6M+201.5% | $8.6M+201.5% | $8.4M+197.2% | $8.4M+197.2% | $2.8M0.0% | $2.8M0.0% | $2.8M0.0% |
| Total Liabilities | $28.1M+31.1% | $26.3M+282.7% | $26.7M+264.3% | $23.1M+200.9% | $21.4M+125.9% | $6.9M-38.7% | $7.3M-29.0% | $7.7M-25.2% |
| Current Liabilities | $20.4M+217.3% | $17.9M+281.6% | $18.1M+263.1% | $7.4M+45.1% | $6.4M-3.3% | $4.7M-41.7% | $5.0M-31.7% | $5.1M-28.5% |
| Non-Current Liabilities | $7.7M-48.5% | $8.4M+285.1% | $8.6M+266.8% | $15.7M+513.3% | $15.0M+426.8% | $2.2M-31.0% | $2.4M-22.4% | $2.6M-17.7% |
| Long-Term Debt | $366K-95.3% | $418K | $469K-60.9% | $8.4M+598.3% | $7.8M+546.7% | N/A | $1.2M0.0% | $1.2M0.0% |
| Total Equity | -$3.8M-183.2% | -$1.1M-125.8% | -$1.5M-118.7% | $2.5M-67.0% | $4.6M-27.8% | $4.4M+657.2% | $8.0M+1835.3% | $7.7M+16563.0% |
| Retained Earnings | -$138.5M-22.5% | -$133.0M-23.1% | -$125.4M-20.3% | -$118.5M-16.9% | -$113.1M-14.5% | -$108.1M-11.6% | -$104.2M-12.0% | -$101.4M-14.2% |
Not reported in any period shown, so not listed: Inventory.
VVOS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1M+9.9% | -$6.0M-58.3% | -$3.8M-29.7% | -$4.2M+0.6% | -$3.5M-14.6% | -$3.8M-50.9% | -$2.9M-7.0% | -$4.2M-49.5% |
| Depreciation & Amortization | $510K+66.7% | $454K+156.5% | $442K+206.9% | $384K+163.0% | $306K+111.0% | $177K+21.2% | $144K-3.4% | $146K-2.7% |
| Stock-Based Compensation | $100K-66.7% | $151K-52.4% | N/A | $100K0.0% | $300K-50.0% | $317K+8.2% | N/A | $100K-50.0% |
| Capital Expenditures | $416K-46.0% | $18K-85.2% | $1.5M+827.9% | -$83K-56.8% | $771K+1185.0% | $122K-19.2% | $165K0.0% | $192K+24.7% |
| Free Cash Flow | -$3.6M+16.4% | -$6.0M-53.9% | -$5.3M-72.1% | -$4.2M+3.1% | -$4.3M-37.2% | -$3.9M-46.9% | -$3.1M-6.6% | -$4.4M-48.2% |
| Investing Cash Flow | -$416K+93.0% | -$18K+85.2% | -$1.6M-858.2% | $83K+143.2% | -$5.9M-9743.3% | -$122K+19.2% | -$165K0.0% | -$192K-24.7% |
| Financing Cash Flow | $3.2M | $6.1M | $4.3M+41.9% | $2.8M-27.0% | N/A | N/A | $3.1M-14.4% | $3.8M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VVOS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.3%+2.1pp | 59.5%+9.5pp | 78.1%+21.4pp | 58.0%-2.4pp | 55.2%-10.2pp | 50.0%-6.6pp | 56.7%-7.6pp | 60.5%+7.6pp |
| Operating Margin | -93.6% | -128.7% | -166.8% | -69.8%-1.3pp | -127.4% | -129.9% | -75.8% | -68.5% |
| Net Margin | -106.4% | -149.4% | -180.3% | -79.6%-11.8pp | -131.2% | -128.1% | -76.4% | -67.8%-4.4pp |
| Return on Equity | N/A | N/A | N/A | -213.3%-179.1pp | -109.4%-79.0pp | -87.7%+558.9pp | -35.5%+1000.7pp | -34.1%+4515.9pp |
| Return on Assets | -22.7%-3.4pp | -30.7%+3.6pp | -27.4%-8.9pp | -21.1%-4.0pp | -19.3%-7.1pp | -34.3%-2.4pp | -18.5%+21.2pp | -17.1%+3.2pp |
| Current Ratio | 0.21-0.8x | 0.27-0.5x | 0.24-1.3x | 0.78-0.7x | 1.05-0.1x | 0.77+0.3x | 1.50+1.2x | 1.44+1.2x |
| Debt-to-Equity | N/A | N/A | N/A | 3.31+3.2x | 1.69+1.5x | 1.56-17.7x | 0.15-2.8x | 0.16-25.9x |
| Asset Turnover | 0.21+0.1x | 0.21-0.1x | 0.15-0.1x | 0.260.0x | 0.15-0.1x | 0.270.0x | 0.24-0.1x | 0.25-0.1x |
| FCF Margin | -69.2% | -117.3% | -139.7% | -62.6% | -111.7% | -129.9% | -84.0%+5.7pp | -113.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$1.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.24), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Vivos Therapeutics Inc VVOS | FY2025 | $17.4M | -$21.2M | N/A | $3.7M | 21/100 |
| Adagio Medical ADGM | FY2025 | $0 | -$25.1M | N/A | $12.5M | — |
| Nortech Sys Inc NSYS | FY2025 | $118.4M | -$252K | -0.2% | $33.4M | 37/100 |
| Envoy Medical COCH | FY2025 | $241K | -$23.8M | N/A | $55.0M | — |
| Myomo MYO | FY2025 | $40.9M | -$15.6M | -38.1% | $57.0M | 43/100 |
| Iridex IRIX | FY2025 | $52.7M | -$4.4M | -8.4% | $12.2M | 50/100 |
Where Vivos Therapeutics Inc Ranks
Frequently Asked Questions
What is Vivos Therapeutics Inc's annual revenue?
Vivos Therapeutics Inc (VVOS) reported $17.4M in total revenue for fiscal year 2025. This represents a 16.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Vivos Therapeutics Inc's revenue growing?
Vivos Therapeutics Inc (VVOS) revenue grew by 16.0% year-over-year, from $15.0M to $17.4M in fiscal year 2025.
Is Vivos Therapeutics Inc profitable?
No, Vivos Therapeutics Inc (VVOS) reported a net income of -$21.2M in fiscal year 2025.
What is Vivos Therapeutics Inc's EBITDA?
Vivos Therapeutics Inc (VVOS) had EBITDA of -$18.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Vivos Therapeutics Inc have?
As of fiscal year 2025, Vivos Therapeutics Inc (VVOS) had $2.0M in cash and equivalents against $469K in long-term debt.
What is Vivos Therapeutics Inc's gross margin?
Vivos Therapeutics Inc (VVOS) had a gross margin of 60.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Vivos Therapeutics Inc's free cash flow?
Vivos Therapeutics Inc (VVOS) recorded an outflow of $17.6M in free cash flow during fiscal year 2025. This represents a -32.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Vivos Therapeutics Inc's operating cash flow?
Vivos Therapeutics Inc (VVOS) recorded an outflow of $15.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Vivos Therapeutics Inc's total assets?
Vivos Therapeutics Inc (VVOS) had $25.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Vivos Therapeutics Inc's capital expenditures?
Vivos Therapeutics Inc (VVOS) invested $2.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Vivos Therapeutics Inc spend on research and development?
Vivos Therapeutics Inc (VVOS) invested $100K in research and development during fiscal year 2025.
What is Vivos Therapeutics Inc's current ratio?
Vivos Therapeutics Inc (VVOS) had a current ratio of 0.24 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Vivos Therapeutics Inc's return on assets (ROA)?
Vivos Therapeutics Inc (VVOS) had a return on assets of -84.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Vivos Therapeutics Inc's P/E ratio?
Vivos Therapeutics Inc (VVOS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $3.7M as of Sep 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Vivos Therapeutics Inc's price-to-sales ratio?
Vivos Therapeutics Inc (VVOS) trades at 0.2x sales, its market capitalization divided by revenue of $20.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $3.7M as of Sep 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Vivos Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Vivos Therapeutics Inc (VVOS) held $2.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.3M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Vivos Therapeutics Inc's debt-to-equity ratio negative or not reported?
Vivos Therapeutics Inc (VVOS) has negative shareholder equity of -$1.5M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Vivos Therapeutics Inc's Altman Z-Score?
Vivos Therapeutics Inc (VVOS) has an Altman Z-Score of -9.46, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Vivos Therapeutics Inc's Piotroski F-Score?
Vivos Therapeutics Inc (VVOS) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Vivos Therapeutics Inc's earnings high quality?
Vivos Therapeutics Inc (VVOS) reported a net loss of $21.2M while operations used $15.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Vivos Therapeutics Inc cover its interest payments?
Vivos Therapeutics Inc (VVOS) reported an operating loss of $19.9M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Vivos Therapeutics Inc?
Vivos Therapeutics Inc (VVOS) scores 21 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.